Financials
This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQANIK
| Beta | 0.98 |
|---|---|
| Shares Outstanding | 14.6M |
| Average Volume (10 days) | 92.1K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 1 | |
|---|---|---|
| Buy | 0 | |
| Hold | 1 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
John B. Henneman Director | 7,954 Acquire Jun 8, 2022 |
|---|---|
Sheryl L. Conley Director | 7,954 Acquire Jun 8, 2022 |
Susan L.N. Vogt Director | 7,954 Acquire Jun 8, 2022 |
Stephen Richard Director | 7,954 Acquire Jun 8, 2022 |
Glenn R. Larsen Director | 7,954 Acquire Jun 8, 2022 |